Explore 3 Stock Ideas & Industry Insights Download Free Report

Solvonis Therapeutics plc

Company price
0.091 GBX -0.00 ( 4.21%)
Last update at 2026-10-27T15:52:00Z
VOLUME
28963537
Market Cap
17.70M

Momentum Score

…

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.09
Low
0.10
High
52 Week Price Range
0.11
Low
0.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.10
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-60.51%
Net Debt
-0.76M
ROCE
-44.84%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2021-05-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2021-05-31
Income before tax -1.45M -3.12M -2.71M -0.95M -0.27M
Net income -1.59M -3.12M -2.71M -0.95M -0.27M
Selling general administrative 0.80M 0.68M 2.67M 1.54M 0.35M
Selling and marketing expenses - 1.40M 0.01M 0.64M 0.28M
Gross profit 0.00M -0.13M -0.05M 0.06M 0.52M
Reconciled depreciation 0.00M 0.18M 0.11M - 0.11M
Ebit - -3.12M -2.70M -0.95M -0.44M
Ebitda -1.38M -2.94M -2.59M -0.90M -0.32M
Depreciation and amortization - 0.18M 0.11M 0.05M 0.12M
Operating income -1.38M -3.12M -2.71M -0.84M -0.11M
Other operating expenses 1.38M 3.70M 3.25M 1.06M 0.80M
Interest expense 0.06M 0.00M 0.00M 0.01M 0.01M
Tax provision 0.00M 0.00M 0.00M - 0.00M
Net interest income -0.06M -0.00M -0.00M - -0.01M
Income tax expense - - - - -0.00M
Total revenue 0.00M 0.59M 0.54M 0.22M 0.69M
Total operating expenses 1.38M 3.26M 2.66M 0.90M 0.63M
Cost of revenue 0.00M 0.45M 0.59M 0.16M 0.17M
Total other income expense net -0.06M -0.00M -0.00M -0.11M -0.16M
Net income from continuing ops -1.45M -3.12M -2.71M - -0.45M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2021-05-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2021-05-31
Total assets 3.20M 2.43M 4.94M 3.13M 2.77M
Intangible assets - 2.07M 2.07M 2.07M 2.07M
Other current assets 0.06M 0.04M 0.33M 0.12M -
Total liab 0.12M 0.41M 0.39M 2.32M 1.22M
Total stockholder equity 3.08M 2.03M 4.55M 0.81M 1.54M
Other current liab 0.04M 0.12M 0.14M 0.53M 0.26M
Common stock 2.23M 0.04M 0.04M 0.01M 0.01M
Capital stock 2.23M 0.04M 0.04M 0.01M -
Retained earnings -10.55M -8.96M -5.84M -3.14M -2.19M
Cash 0.76M 0.15M 1.64M 0.60M 0.21M
Total current liabilities 0.12M 0.39M 0.37M 2.32M 1.22M
Current deferred revenue - 0.09M 0.04M - -
Net debt -0.76M -0.12M -1.62M 0.35M 0.45M
Short term debt - 0.01M 0.00M 0.95M 0.68M
Short long term debt - - 0.00M 0.96M -
Short long term debt total - 0.03M 0.02M 0.95M 0.65M
Other stockholder equity 11.41M 14.00M 7.86M 3.94M 3.43M
Total current assets 0.81M 0.31M 2.16M 0.74M 0.26M
Net receivables 0.00M 0.07M 0.04M 0.04M 0.06M
Inventory 0.00M 0.05M 0.19M 0.00M -
Accounts payable 0.08M 0.16M 0.18M 0.84M 0.28M
Accumulated other comprehensive income - 3.95M 3.36M 3.00M -
Non currrent assets other 0.30M 0.01M 0.01M 0.01M 0.01M
Non current assets total 2.39M 2.12M 2.78M 2.39M 2.50M
Capital lease obligations 0.00M 0.03M 0.02M 0.00M -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2021-05-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2021-05-31
Total cashflows from investing activities -0.34M -0.23M -0.72M -0.00M -0.02M
Net borrowings 0.20M 0.00M 0.00M - 0.20M
Total cash from financing activities 2.08M - 4.13M 0.80M 0.20M
Net income -1.59M -3.12M -2.71M -0.95M -0.27M
Change in cash 0.60M -1.49M 1.04M 0.39M 0.12M
Begin period cash flow 0.15M 1.64M 0.60M 0.21M 0.09M
End period cash flow 0.76M 0.15M 1.64M 0.60M 0.21M
Total cash from operating activities -1.13M -1.24M -2.36M -0.25M 0.00M
Issuance of capital stock 1.92M 0.00M 4.47M - 0.00M
Depreciation 0.00M 0.18M 0.11M 0.05M 0.12M
Other cashflows from investing activities -0.32M - - - -
Change to inventory 0.00M 0.01M -0.19M - -
Change to account receivables 0.03M 0.01M 0.04M -0.06M -0.04M
Other cashflows from financing activities -0.04M - -0.34M 0.80M -
Capital expenditures 0.00M 0.23M 0.72M 0.00M 0.02M
Change in working capital -0.03M 0.41M -0.64M 0.65M 0.16M
Stock based compensation 0.32M 0.37M 0.86M - -
Other non cash items 0.17M 0.92M 1.74M -0.55M -0.01M
Free cash flow -1.13M -1.47M -3.08M -0.26M -0.01M

Peer Comparison*

Sector: Industrials Industry: Specialty Industrial Machinery

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SVNS
Solvonis Therapeutics plc
-0.00
4.21%
0.09 - - 9.59 2.55 10.28 -19.66
MYSE
Ming Yang Smart Energy Group Ltd. GDR
-
-%
7.20 0.81 12.08 0.00 0.81 0.11 2.09
WEIR
Weir Group PLC
22.00
0.85%
2598.00 32.23 20.92 3.10 3.93 3.42 15.64
SMIN
Smiths Group PLC
13.00
0.49%
2679.00 33.28 14.84 2.58 4.36 2.78 14.32
IMI
IMI PLC
-8.00
0.28%
2862.00 22.27 18.59 2.92 5.70 2.97 12.23

Profile*

Solvonis Therapeutics plc

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

Eccleston Yards, London, United Kingdom, SW1W 9NF

44 77 9543 0246

3

Name Title Year Born
Mr. Anthony James Tennyson CEO & Executive Director 1976
Mr. Victor Bolduev Founder 1957
Mr. Ryan Paul Neates Chief Financial Officer 1991
Prof. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D. Chief Scientific Advisor NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…